Actively Recruiting
ICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock
Led by Rennes University Hospital · Updated on 2024-10-08
130
Participants Needed
5
Research Sites
235 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Immunonutrition in intensive care has not yet demonstrated a beneficial effect on organ failure, the acquisition of nosocomial infections, or mortality. It did not correct for acquired immunosuppression in intensive care patients. Despite numerous methodological problems (use of several pharmaconutrients, very heterogeneous set of patients) and the absence of clinical data, deleterious effects have been attributed to immunonutrition in intensive care, in particular in septic patients and patients in intensive care . Arginine (ARG) is a semi-essential amino acid involved in many immunological mechanisms. It is synthesized in sufficient quantity under normal conditions but quickly becomes insufficient under catabolic conditions such as in severe sepsis. Arginine is not only the precursor of nitrogen monoxide (NO) but also an essential substrate for numerous enzymatic reactions which participate in the maintenance of immune homeostasis, in particular T lymphocyte function. Depletion of the cellular medium in arginine will induce an abnormality in the metabolism of immune cells responsible for a dysfunction of these cells (lymphopenia linked to early apoptosis) and thus expose patients to organ failure and nosocomial infections. It has been found that hypoargininemia in intensive care patients is associated with the persistence of organ dysfunction (SOFA score), the occurrence of nosocomial infections and mortality. Also, it has been demonstrated that in these patients, enteral administration of ARG was not deleterious and increased ornithine synthesis, suggesting a preferential use of ARG via the arginases route, without significant increase in argininaemia or effect on immune functions. L-citrulline (CIT), an endogenous precursor of ARG, constitutes an interesting alternative for increasing the availability of ARG. Sponsor recent data demonstrate that the administration of CIT in intensive care is not deleterious and that it very significantly reduces mortality in an animal model of sepsis, corrects hypoargininemia, with convincing data on immunological parameters such as lymphopenia, which is associated with mortality, organ dysfunction and the occurrence of nosocomial infections. The availability of ARG directly impacts the mitochondrial metabolism of T lymphocytes and their function. Our hypothesis is therefore that CIT supplementation is more effective than administration of ARG in correcting hypoargininemia, reducing lymphocyte dysfunction, correcting immunosuppression and organ dysfunction in septic patients admitted to intensive care.
CONDITIONS
Official Title
ICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with sepsis or septic shock as defined by 2016 guidelines from the European Society of Intensive Care Medicine
- Initial infection signs started less than 4 days before ICU admission
- Hospitalized for less than 48 hours before ICU admission
- Receiving invasive mechanical ventilation with expected duration over 2 days
- Receiving exclusive enteral nutrition
- Affiliated with a social security scheme
- Provided signed consent or included under emergency procedure
You will not qualify if you...
- Progressive Sars-CoV2 infection
- Current pregnancy
- Morbid obesity with BMI over 40
- Immunosuppression due to steroids over one month, high-dose steroids, recent radiotherapy or chemotherapy, or proven immune deficiency
- Contraindications to enteral nutrition such as high flow digestive fistula, intestinal obstruction, small intestine ischemia, or active digestive hemorrhage
- Participation in other research affecting immune system
- Receiving immunosuppressive therapy like chemotherapy or high dose corticosteroids (except hydrocortisone for septic shock)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Rennes University Hospital - Medical ICU
Rennes, Brittany Region, France, 35033
Actively Recruiting
2
Rennes University Hospital - Surgical ICU
Rennes, Brittany Region, France, 35033
Terminated
3
Besançon University Hospital
Besançon, France, 25000
Actively Recruiting
4
Le Mans Hospital
Le Mans, France, 72037
Actively Recruiting
5
Tours University Hospital
Tours, France, 37044
Actively Recruiting
Research Team
M
Mathieu Lesouhaitier, MD
CONTACT
J
Jean-Marc Tadié, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here